Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748524 · ClinicalTrials.gov registry record · Early Phase 1
Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT03748524 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 11 participants.
The verdict
NCT03748524, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph nodes at baseline, days, 4, 14, 28, 60 and 180. BMA at baseline, days 28 and 180.
Interventions
- DRUG Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2022-06-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03748524
The ClinicalTrials.gov registry entry for NCT03748524 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Vaccine is the first listed.
NCT03748524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03748524 about?
NCT03748524 is a clinical study titled "Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine". Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph nodes at baseline, days, 4, 14, 28, 60 and 180. BMA at baseline, days 28 and 180.
What is the current status of trial NCT03748524?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2018-10-29. Estimated completion is 2022-06-20.
What interventions are being tested in trial NCT03748524?
The interventions under investigation include: Influenza Vaccine (DRUG).
Who is sponsoring clinical trial NCT03748524?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.